Lixisenatide vs Mazdutide

Lixisenatide (brand names Adlyxin and Soliqua) is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes, and it’s taken as an injection. Mazdutide, on the other hand, is an experimental drug that acts on both GLP-1 and glucagon receptors (a dual agonist) and has not yet been approved for any use.

AI summary of the sources below.